Despite the clinical success of immunotherapies based on immune checkpoint inhibitors (i.e., antibodies against the immune regulators CTLA4 and PD-L1/PD-1), unfortunately, only a subset of patients respond to this treatment, suggesting that cancer immune evasion is a major barrier in current immunotherapy. Here, CTLA4 is linked to cancer.